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Mastitomics, the integrated omics of bovine milk
in an experimental model of Streptococcus uberis
mastitis: 2. Label-free relative quantitative
proteomics†
Manikhandan Mudaliar,ab Riccardo Tassi,c Funmilola C. Thomas,a Tom N. McNeilly,c
Stefan K. Weidt,b Mark McLaughlin,d David Wilson,b Richard Burchmore,be
Pawel Herzyk,bf P. David Eckersalla and Ruth N. Zadoks*ac
Mastitis, inflammation of the mammary gland, is the most common and costly disease of dairy cattle in
the western world. It is primarily caused by bacteria, with Streptococcus uberis as one of the most
prevalent causative agents. To characterize the proteome during Streptococcus uberis mastitis, an
experimentally induced model of intramammary infection was used. Milk whey samples obtained from
6 cows at 6 time points were processed using label-free relative quantitative proteomics. This proteomic
analysis complements clinical, bacteriological and immunological studies as well as peptidomic and
metabolomic analysis of the same challenge model. A total of 2552 non-redundant bovine peptides
were identified, and from these, 570 bovine proteins were quantified. Hierarchical cluster analysis and
principal component analysis showed clear clustering of results by stage of infection, with similarities
between pre-infection and resolution stages (0 and 312 h post challenge), early infection stages (36 and
42 h post challenge) and late infection stages (57 and 81 h post challenge). Ingenuity pathway analysis
identified upregulation of acute phase protein pathways over the course of infection, with dominance of
diﬀerent acute phase proteins at diﬀerent time points based on diﬀerential expression analysis.
Antimicrobial peptides, notably cathelicidins and peptidoglycan recognition protein, were upregulated at
all time points post challenge and peaked at 57 h, which coincided with 10000-fold decrease in average
bacterial counts. The integration of clinical, bacteriological, immunological and quantitative proteomics
and other-omic data provides a more detailed systems level view of the host response to mastitis than
has been achieved previously.
1. Introduction
Bovine milk is a complex physiological secretion and contains
protein at an average concentration of 32 g L1. Caseins form
80% of the total milk protein while whey proteins constitute
about 16% of the total milk protein.1 Whey comprises several
hundred heterogeneous, mostly water-soluble proteins including
beta-lactoglobulin, alpha-lactalbumin, blood serum albumin and
immunoglobulins (IgG, IgA, IgM and IgE). These proteins have a
number of functions such as ion binding, protein binding,
carbohydrate binding, pattern binding, cell surface binding, lipid
binding, enzyme regulating, cell-to-cell signalling and cell cycle
regulating activities.1,2 There are substantial changes in the whey
proteome (the set of proteins present in whey) during mastitis,
inflammation of the mammary gland. The pathogenesis of
mastitis, which is largely due to intra-mammary infections
(IMI), includes an inflammatory reaction involving the release
of cytokines and acute-phase proteins (APP).3,4 Several studies
have shown changes in the milk or whey proteome due to
mastitis.5–7
This is the second of three studies integrating omic
approaches to the investigation of experimentally induced
mastitis with Streptococcus uberis, a major cause of the disease
in the UK and many other parts of the world.8 Using the same
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milk samples, temporal changes in the milk peptidome,4
proteome (this paper) and metabolome9 were determined during
the acute phase of infection and its resolution. The peptidome was
considered to consist of peptides, polypeptides and short protein
sequences, usually degradation-derived protein fragments, with
masses between B400 Da and B20 000 Da.4 The proteome
includes whole proteins with masses ranging up to 3 MDa,10
which can be experimentally broken down into peptide pools
using proteolytic enzymes, usually trypsin, and identified by
comparing the mass spectra from experiments with the theore-
tical enzyme-specific fragmentation patterns derived from
protein sequences. Finally, the metabolome consists of the
entirety of molecules, small and large, that undergo metabolism,
most of which have a mass less than 1500 Da, with the exception
of lipids, which have masses up to 5000 Da.10
In addition to identification, quantitation of proteins in
complex biological samples is possible.10,11 The classical
method used for quantitative analysis of complex mixtures of
proteins such as milk is by protein separation and comparison
by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE),
followed by mass spectrometry (MS) analysis.11,12 However, the
gel-based quantitative proteomics techniques are laborious and
suﬀer poor representation of hydrophobic, very high or low
molecular weight proteins.11 To overcome the shortcomings of
the gel-based methods and to increase the dynamic range and
quantitative accuracy, non-gel-based quantitative proteomics
methods have been developed.11,13 Non-gel-based quantitative
proteomics approaches can be divided into methods using
metabolic or chemical labelling and label-free approaches.13
Some of the labelling approaches utilize isotope-labelled com-
pounds (such as isotope labelled amino acids) that are functionally
and chemically identical to the properties of their unlabelled
equivalent except in mass, which allows for their discrimination
in mass spectrometry. Stable labelling approaches include stable
isotope labelling by amino acids in cell culture (SILAC), isotope-
coded aﬃnity tag (ICAT), isobaric tags for relative and absolute
quantification (iTRAQ), dimethyl labelling and tandem mass
tags.13–15 Label-free relative quantification is an alternative method
that can be applied to clinical samples, and offers better
dynamic range than some labelling approaches15–17 and requires
minimal manipulation of samples, which reduces the possibility
of introducing artefactual changes.
In this study, we describe the application of a label-free
relative quantification method to analyse the quantitative
changes in the proteome of bovine milk whey in the experimental
model of S. uberis mastitis and compare those to data obtained
from clinical, immunological, and peptidomic studies.
2. Materials and methods
Cows (n = 6) were challenged with Streptococcus uberis strain
FSL Z1-048 in a single bacteriologically negative udder quarter
per cow as previously described.3 Aliquots of milk samples
collected from six time points (0, 36, 42, 57, 81 and 312 hours
post-challenge (PC)) were used to generate quantitative label-free
proteomics data. These were the same samples as used in the
associated peptidomic4 and metabolomic9 studies and were
selected on the basis of clinical manifestation, bacterial load and
SCC.3 Body temperature of the cows and bacterial concentrations
in milk from challenged quarters peaked from 24 h (bacteria) or
30 h (temperature) PC up to 57 h PC and had decreased to a
plateau by 81 h PC, whereby body temperature had returned to
normal and bacterial concentrations in culture positive quarters
stayed constant until the end of the study at 312 h PC. The
challenge study was conducted at the Moredun Research Institute
(Penicuik, UK) and had received ethical approval from the Institute’s
Experiments and Ethical Review Committee in accordance with the
UK’s Animals (Scientific Procedures) Act 1986.3
2.1 Label-free quantitative proteomic data generation
2.1.1 Separation of whey. The aliquots of frozen skimmed
milk samples,3 ranging between 0.5 mL and 1.5 mL in volume
per sample, were thawed at 4 1C. The volume of every sample
was brought to 1.5 mL using phosphate buﬀered saline (PBS).
To remove the residual milk fat globules and cell pellets, the
samples were centrifuged at 13 000  g for 30 min at 4 1C in an
Eppendorf centrifuge (model 5804R) with a fixed-angle rotor
(FA-45-30-11). Using a pipette, the middle clear portion (1 mL)
was carefully drawn from each sample and transferred into an
ultracentrifuge tube (Beckman Coulter Thickwall polycarbonate,
part no. 343778) and centrifuged in a Beckman Coulter benchtop
ultracentrifuge (model TL-100) with a fixed-angle rotor (TLA-100.2)
at 150000  g (59 000 rpm) for 60 minutes at 4 1C. Most of the
caseins in the samples sedimented to the bottom of the ultra-
centrifuge tubes, and above them exosomes formed a loose pellet
layer with crude whey forming the supernatant. This crude whey
was transferred to a clean ultracentrifuge tube and centrifuged
again at 150000  g for 60 minutes at 4 1C to remove the residual
caseins.7
2.1.2 Whey protein extraction, purification and normalization.
Total protein quantity in the whey was measured by Bradford
protein assay in 250 mL microplate assay format using Bio-Rad
protein assay dye reagent concentrate (product no. 500-0006)
and bovine serum albumin (BSA) fraction V (Roche, product no.
10735086001) as the standard. To remove substances that
might interfere with downstream proteomic analysis, proteins
from whey were purified by precipitating them with absolute
acetone.7,18 Using the measured total protein concentration
in each sample, whey was diluted with HPLC grade water to
2 mg mL1 total protein. For every diluted whey sample, an
aliquot of 100 mL was transferred into a 1.5 mL micro test tube
and six volumes (600 mL) of ice-cold 100% acetone (VWR
International, product no. 20066.330) was added and kept
at 80 1C for 12 hours. Precipitated proteins were centrifuged
at 20 000  g for 40 minutes at 4 1C in an Eppendorf
centrifuge (model 5804R). The supernatant was discarded,
and the pellets (precipitated proteins) were washed three times
with 400 mL of 80% (v/v) acetone to remove salts, and then dried
under a fume hood for 10 minutes. The dried pelleted proteins
from each sample were re-suspended in 50 mL of 50 mM
ammonium bicarbonate (Sigma-Aldrich, product no. A6141)
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buﬀer (NH4CO3 buﬀer) and the extracted protein quantity
was measured by Bradford protein assay as described before.
The re-suspended proteins in each sample were normalized by
diluting them with the required volume of NH4CO3 buﬀer to
arrive at 2.5 mg mL1 total protein concentration.
2.1.3 Preparation of trypsin digests. For every sample, an
aliquot of 40 mL of the normalized re-suspended proteins,
containing 100 mg of total proteins in buﬀer was transferred
into a 1.5 mL micro test tube. For each aliquot, 12 mL of
10% (w/v) sodium deoxycholate (SDC) solution in buﬀer
(Sigma-Aldrich, product no. D6750), 8 mL of 80% (v/v) aceto-
nitrile (Fisher Scientific, product no. 10660131) in buﬀer and
50 mL of 10% (w/v) modified trypsin (Promega, product no.
V5111) in trypsin re-suspension buﬀer were added. The digest
was incubated for 18 hours at 37 1C in a heating block. Then,
12 mL of 1% (v/v) formic acid (Sigma-Aldrich, product no.
94318) was added to the digest (final formic acid concen-
tration 0.1%) to precipitate SDC, and samples were centri-
fuged at 16 000  g for 10 minutes at 4 1C. For every sample,
supernatant containing 2 mg (calculated) of digested protein
was transferred into a well of a conical bottommicroplate and dried
in a SpeedVac (Thermo Fisher Scientific, model no. SPD1010).
2.1.4 On-line liquid chromatography and tandem mass
spectrometry. For on-line reversed-phase liquid chromato-
graphy and mass spectrometry (LC-MS), a Dionex UltiMate
3000 RSLCnano (liquid chromatography) system coupled to
a Thermo Scientific Orbitrap Elite mass spectrometer was used.
A stainless steel Nano-Trap column with 300 mm inside diameter,
5 mm length, particle size 5 mm and pore size 10 nm, packed with
stationary phase Acclaim PepMap C18 (Thermo Scientific, part no.
160454) and a resolving Nano LC column with 75 mm inside
diameter, 15 cm length, particle size 2 mm and pore diameter
10 nm with stationary phase Acclaim PepMap RSLC C18 (Thermo
Fisher Scientific, part no. 164534) were used in the HPLC. The
dried protein digests in the microplate were loaded on the Rapid
Separation LC (RSLC) Autosampler connected to the C18 trap
column equilibrated in 96% solution A (0.1% formic acid in
HPLC grade water (v/v)) and 4% solution B (80% acetonitrile and
0.08% formic acid in HPLC grade water (v/v)) with a flow rate of
25 mL min1. The trap column was washed for 12 minutes at the
same flow rate and then switched to the in-line resolving C18
column. A constant flow rate of 300 nL min1 was maintained
with a linear gradient from 4% solution B to 40% solution B in
108 minutes, then to 100% solution B by the 124th minute. Then
the column was washed with 100% solution B for 5 minutes
followed by recalibration with 96% solution A for 6 minutes.
In the mass spectrometer, one scan cycle comprised MS1 scan
(m/z range from 400–2000) in the Orbitrap Elite followed by up
to 20 data-dependent MS2 scans (threshold value 1000 and
maximum injection time 200 ms) in the Velos LTQ in collision-
induced dissociation (CID) mode. To account for any retention
time drift, carryover or other errors that might occur during the
run, the sample loading order was randomized using Microsoft
Excel. After every six samples, a blank was analysed to monitor
carryover. All samples were run consecutively without breaks,
which took about 4 days of mass spectrometer time.
2.2 Label-free quantitative proteomic data analysis
2.2.1 Exploration of the raw data. The raw MS/MS data
obtained from each sample were visually examined by generat-
ing a number of plots using MZmine (version 2.10) software.19
To examine sample loading and peak resolution, total ion
current (TIC) chromatograms and base peak chromatograms
were generated from the MS1 data obtained from each sample.
To detect chromatographic shifts in retention time, MS1 spectra
were visualized by generating 2D and 3D plots using the 2D and
3D plot functions in MZmine software. In addition, 2D plots and
TIC chromatograms of the MS1 spectra were generated using the
integrated viewer in the MaxQuant software (version 1.5.2.8)20
and examined for overall consistency and retention time shifts
between the samples.
2.2.2 Peptide identification and protein quantification.
After initial quality control, the raw MS/MS data from all
samples and blanks were imported into MaxQuant software
(version 1.5.2.8) for label-free relative quantification analysis.21
Feature detection and mass recalibration were automatically
performed in MaxQuant, and peptides were identified using its
integrated Andromeda search engine.22 Reporter quantifica-
tion, retention time alignment, protein assembly, label-free
quantification and MaxLFQ normalization were also performed
in MaxQuant.23 For identification and quantification, N-terminal
acetylation, oxidation of methionine and deamidation of asparagine
or glutamine were set as variable modifications, and carbamido-
methylation of cysteines was set as a fixed modification. For
in silico digestion, Trypsin/P was used and a maximum of 2
missed cleavages were allowed. Up to 6 ppm peptide mass
tolerance was allowed during the main search. A false discovery
rate (FDR) up to 1% was allowed for peptide spectrum match
and protein assembly, and the FDR was estimated using the
reversed peptide sequences. At least one unique or ‘‘razor’’
peptide was required for identification. For label-free quantifi-
cation, the ‘Fast LFQ’ option was turned oﬀ and a minimum of
one quantified peptide pair was required for pair-wise compar-
isons of a protein between two samples. The ‘match-between-
runs’ option with a match time window of 2 minutes was used to
transfer identifications across the replicate experiments, whereby
the 6 individual cows were treated as biological replicates for each
time point. In addition, absolute protein quantitation was per-
formed using the intensity based absolute quantification (iBAQ)
method.
Proteins from the Bos taurus proteome were identified using
the 23 868 protein reference proteome (UniProt Proteome ID:
UP000009136; last modified 10 May 2015), which was down-
loaded from the UniProt Knowledgebase and imported into the
Andromeda search engine. Conflicts of multiple protein assign-
ments were manually resolved taking into account the peptide
counts, the razor and/or unique peptide counts, and the
evidence status of the protein annotation (annotation score)
in the UniProt database. Where a protein was identified based
on comparison with both the Bos taurus reference proteome
and the MaxQuant contaminant list, they were assigned to Bos
Taurus, because many proteins on this list, e.g. keratin or
bovine serum proteins, are of bovine.24
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2.2.3 Statistical analysis. Statistical analysis was performed
using Perseus (version 1.5.2.6), the Partek Genomics Suite
(version 6.6, Partek Inc., St. Louis) and R (version 3.1.2) soft-
ware. The normalized protein intensities from the MaxQuant
analysis were imported into Perseus software. Protein intensities
(abundances) in the linear scale were transformed into logarithmic
scale with base two. The missing values were replaced with a
constant value of 10 to simulate signals from low abundant
proteins. For exploratory analysis, histograms were generated to
examine the dataset. Hierarchical clustering analysis and principal
component analysis (PCA) were performed using Perseus and
Partek Genomics Suite software. To identify diﬀerentially
expressed proteins one-way analysis of variance (ANOVA) was
performed with time as factor. From the ANOVA results, protein
lists were created by comparing each time-point PC to the pre-
challenge results (0 h PC). Proteins with an absolute fold
change 42 and FDR-adjusted p-value o 0.05 were considered
diﬀerentially expressed and included in the protein lists.
2.2.4 Pathway analysis. The diﬀerentially expressed pro-
teins were analysed for enrichment of canonical pathways
using ingenuity pathway analysis (IPA) software (QIAGEN, Red-
wood City, CA) and the STRING database (version 10.0) and
search tool.25 IPA computes an enrichment score for the over-
lap between the observed and the predicted regulated gene sets
using a Fisher’s exact test and p-value 40.05. The direction of
regulation, i.e. up- or downregulation, was inferred from the
activation z-score in the IPA.26 In addition, the ratio of identified
(i.e. present in the sample) to potentially identifiable proteins
(i.e. present in the pathway) is calculated for each pathway.
3. Results
3.1 Quantification and analysis of bovine proteins
TIC chromatograms, base peak chromatograms and 2D plots
were generated for each sample and showed overall consistency
with a retention time drift of about 2 minutes, demonstrating
high quality of the raw data (Fig. S1, ESI†). A total of 2552 non-
redundant bovine peptides were quantified, and 570 proteins
were assembled from the quantified peptides (Table S1, ESI†).
Exploratory data analysis such as histograms, hierarchical
clustering analysis (HCA) and principal components analysis
(PCA) were performed on the quantified protein data.
3.1.1 Hierarchical clustering analysis. To explore the data-
set, HCA using Euclidean distance and average linkage was
performed on the 570 proteins that were quantified from the
cow reference proteome. The analysis (Fig. 1) shows three
major clusters in the column dendrogram, corresponding to
Fig. 1 Heat map of the bovine proteome after intramammary challenge with Streptococcus uberis with hierarchical clustering analysis of cow and time.
This heat map is based on 570 proteins. Hierarchical clustering analysis was performed using Euclidean distance as distance metric and average linkage as
agglomeration method. Clusters are identified by letters (C = pre-challenge and resolution stage; B = early to peak infection based on bacterial numbers;
A = post peak infection), time points by colours (see inset), and individual cows by numbers. Scale bar indicates intensity of upregulation on a log 2 scale.
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diﬀerent phases of the infection process. Cluster C includes samples
from before challenge (0 h PC) and at late resolution stage (312 h
PC), by which time 5 of 6 cows had cleared the infection.3 It also
includes 36 h and 42 h PC samples from cow 5, which was
previously identified as a late responder based on clinical signs
and cytokine profiling.3 Cluster B includes samples from 36 and
42 h PC, corresponding to the early stage of infection, which is
characterized by bacterial growth and neutrophil influx.3 Cluster A
predominantly contains samples from 57 h and 81 h PC, during
which time bacterial numbers had started to decrease.3
3.1.2 Principal component analysis. To further examine
the set of 570 bovine proteins, PCA was performed (Fig. 2).
The PCA shows clustering of samples by time-point with a few
exceptions. As in HCA, results are similar for the pre-challenge
(0 h) and resolution time points (312 h). Samples collected at
81 h PC were most divergent. Outliers at 36 and 42 h PC, which
cluster with samples from 0 h, correspond to the slow responder
(cow 5) that is also visible in Fig. 1 and in clinical, bacteriologic
and inflammatory parameters.3
3.1.3 Diﬀerential expression analysis. One-way ANOVA was
performed with time as factor to identify proteins that were
diﬀerentially expressed between pre- and post-challenge time
points. No distinction was made between proteins that were
detected in all samples and those that were detected in a subset
of samples only, but this information is reflected in the LFQ
intensities (quantities) listed in ESI,† Table S1 where intensity
is shown as 0 if a protein is not detected. Diﬀerentially
expressed protein lists were created for each time point,
and proteins with an absolute fold change more than 2 and
FDR-adjusted p-value less than 0.05 were included in the
protein lists. For time points 36, 42, 57, 81 and 312 h PC, there
were 76 (54 upregulated, 22 downregulated), 126 (96 upregulated,
30 downregulated), 237 (186 upregulated, 51 downregulated), 292
(248 upregulated, 44 downregulated) and 56 (49 upregulated,
7 downregulated) diﬀerentially expressed proteins, respectively
(Table S2, ESI†). The top-15 upregulated and downregulated
bovine proteins for each time point, as compared to 0 h PC, are
given in Tables 1–5. Patterns of up- and down regulation differed
both qualitatively (proteins) and quantitatively (fold change)
between time points, with strongest up- and down-regulation
observed at 57 and 81 h PC. Upregulated proteins include APP,
e.g. haptoglobin and serum amyloid A (SAA); antimicrobial
proteins, e.g. the cathelicidin family and peptidoglycan
recognition protein; and proteins with dual APP and anti-
microbial function, e.g. histidine-rich glycoprotein (HRG) and
lipopolysaccharide-binding protein (LBP). Down-regulated
proteins included cystatin-B, dystroglycan, and mucin-1 in the
early stage of infection (36 and 42 h PC; Tables 1 and 2), and
myozenin-1 and alpha-lactalbumin at the subsequent stage
(57 and 81 h PC; Tables 3 and 4). During the resolution phase
Fig. 2 Principal component analysis (PCA) of the bovine proteome after intramammary challenge with Streptococcus uberis. The PCA was based on
570 proteins and the plot was generated using the Partek Genomic suite. The data points refer to milk samples obtained from 6 cows at 6 time points
post challenge (PC). Cows are identified by number and time points by colour, with hours PC shown in the legend.
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Table 1 Top-15 most up-and down-regulated bovine proteins at 36 hours after intramammary challenge with Streptococcus uberis
Up/down-regulated UniProt ID Protein name Fold change P-Valuea
Up Q8SPP7 Peptidoglycan recognition protein 1 3305 4.5  1010
Up P54229 Cathelicidin-5 1444 1.9  108
Up P56425 Cathelicidin-7 1217 1.6  106
Up P22226 Cathelicidin-1 1026 2.8  108
Up Q2TBU0 Haptoglobin 997 3.8  108
Up F1N465 Uncharacterized protein GN = KBTBD8 527 1.5  103
Up E1BCU6 Uncharacterized protein GN = TCN1 401 1.5  106
Up Q9TU03 Rho GDP-dissociation inhibitor 2 313 1.6  104
Up P52176 Matrix metalloproteinase-9 219 1.1  104
Up P33046 Cathelicidin-4 208 2.7  104
Up Q0VCG9 Pentraxin-related protein PTX3 194 1.5  108
Up Q58CQ9 Pantetheinase 189 8.5  104
Up G3MXK8 Uncharacterized protein (Fragment) GN = PRTN3 167 1.2  103
Up Q28085 Complement factor H 134 1.6  103
Up Q3SZV7 Hemopexin 131 4.9  106
Down P81265 Polymeric immunoglobulin receptor 6 2.0  104
Down Q3MHX6 Protein OS-9 6 4.9  103
Down P10790 Fatty acid-binding protein, heart 7 3.2  104
Down Q8WML4 Mucin-1 38 2.7  103
Down P13696 Phosphatidylethanolamine-binding protein 1 39 1.8  103
Down Q9XSG3 Isocitrate dehydrogenase [NADP] cytoplasmic 50 5.0  105
Down Q9TUM6 Perilipin-2 61 2.0  103
Down E1BLC6 Uncharacterized protein GN = TTC17 67 4.3  103
Down F1N1D2 Uncharacterized protein GN = DMC1 77 4.6  103
Down O18738 Dystroglycan 77 1.2  103
Down P26201 Platelet glycoprotein 4 87 1.0  104
Down E1B9W6 Uncharacterized protein GN = ADCY10 145 2.5  103
Down F6PZ29 Uncharacterized protein GN = MCFD2 191 3.1  103
Down F6QEL0 Cystatin-B 204 1.8  104
Down E1BN90 Uncharacterized protein GN = ZKSCAN2 214 4.6  103
a False discovery rate adjusted.
Table 2 Top-15 most up- or down-regulated bovine proteins at 42 hours after intramammary challenge with Streptococcus uberis
Up/down-regulated UniProt ID Protein name Fold change P-valuea
Up P54229 Cathelicidin-5 9209 1.5  1010
Up P56425 Cathelicidin-7 8922 1.7  108
Up Q8SPP7 Peptidoglycan recognition protein 1 8453 3.7  1011
Up Q2TBU0 Haptoglobin 4794 5.2  1010
Up P22226 Cathelicidin-1 3812 7.6  1010
Up P33046 Cathelicidin-4 2619 1.1  106
Up E1BCU6 Uncharacterized protein GN = TCN1 1292 6.1  108
Up P19660 Cathelicidin-2 1159 3.9  105
Up F1MCC8 Uncharacterized protein GN = NWD1 1144 5.3  104
Up Q0VCG9 Pentraxin-related protein PTX3 963 4.7  1011
Up F1N465 Uncharacterized protein GN = KBTBD8 961 6.0  104
Up F1MKS5 Histidine-rich glycoprotein 775 6.3  106
Up P52176 Matrix metalloproteinase-9 708 7.1  106
Up F1N1F8 Uncharacterized protein GN = CENPF 661 5.7  103
Up Q9TU03 Rho GDP-dissociation inhibitor 2 614 3.8  105
Down P80457 Xanthine dehydrogenase/oxidase 15 1.1  102
Down P02702 Folate receptor alpha 35 5.6  103
Down P29392 Spermadhesin-1 42 8.1  103
Down Q8WML4 Mucin-1 44 1.8  103
Down P08037 Beta-1,4-galactosyltransferase 1 51 1.9  103
Down F1MNS0 Uncharacterized protein GN = HERC1 58 2.6  103
Down P63048 Ubiquitin-60S ribosomal protein L40 70 3.2  103
Down Q0VCX2 78 kDa glucose-regulated protein 73 2.1  103
Down F1N1D2 Uncharacterized protein GN = DMC1 77 4.6  103
Down O18738 Dystroglycan 78 1.2  103
Down P13696 Phosphatidylethanolamine-binding protein 1 87 2.3  104
Down P26201 Platelet glycoprotein 4 87 1.0  104
Down F6QEL0 Cystatin-B 97 9.3  104
Down F6PZ29 Uncharacterized protein GN = MCFD2 201 2.8  103
Down E1BN90 Uncharacterized protein GN = ZKSCAN2 230 4.1  103
a False discovery rate adjusted.
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Table 3 Top-15 most up- or down-regulated bovine proteins at 57 hours after intramammary challenge with Streptococcus uberis
Up/down-regulated UniProt ID Protein name Fold change P-valuea
Up Q8SPP7 Peptidoglycan recognition protein 1 27 479 2.0  1012
Up P54229 Cathelicidin-5 16 618 3.4  1011
Up Q2TBU0 Haptoglobin 14 937 3.0  1011
Up P56425 Cathelicidin-7 11 877 9.1  109
Up P22226 Cathelicidin-1 7281 1.4  1010
Up P33046 Cathelicidin-4 4753 3.0  107
Up Q9TU03 Rho GDP-dissociation inhibitor 2 4748 5.0  107
Up F1N1F8 Uncharacterized protein GN = CENPF 4312 5.9  104
Up F1MYX5 Uncharacterized protein GN = LCP1 2578 3.9  107
Up Q3ZCJ8 Dipeptidyl peptidase 1 2530 7.0  106
Up P02584 Profilin-1 2404 1.0  106
Up P48616 Vimentin 2155 8.2  1011
Up P19660 Cathelicidin-2 2104 1.2  105
Up E1BI67 Uncharacterized protein GN = IL18BP 2095 9.9  107
Up A5PJH7 LOC788112 protein GN = LOC788112 1967 1.9  107
Down P80457 Xanthine dehydrogenase/oxidase 172 1.4  105
Down P79345 Epididymal secretory protein E1 215 4.8  103
Down O18738 Dystroglycan 222 1.1  104
Down Q32KV6 Nucleotide exchange factor SIL1 294 8.8  104
Down P29392 Spermadhesin-1 327 1.3  104
Down E1BGZ9 PHD finger protein 20-like protein 1 337 2.8  103
Down P41541 General vesicular transport factor p115 472 1.2  103
Down E1BN90 Uncharacterized protein GN = ZKSCAN2 585 1.0  103
Down F6PZ29 Uncharacterized protein GN = MCFD2 675 3.9  104
Down Q58DJ3 KIAA1984 824 2.1  103
Down P00711 Alpha-lactalbumin 1022 4.7  106
Down F1MV51 Uncharacterized protein GN = APC 1217 1.0  103
Down Q8SQ24 Myozenin-1 3030 7.2  104
Down E1BNS8 Uncharacterized protein GN = SIK1 4741 3.0  103
Down Q3ZC66 Cysteine-rich PDZ-binding protein 6094 1.5  103
a False discovery rate adjusted.
Table 4 Top-15 most up-and down-regulated bovine proteins at 81 hours after intramammary challenge with Streptococcus uberis
Up/down-regulated UniProt ID Protein name Fold change P-valuea
Up Q2TBU0 Haptoglobin 28 858 6.1  1012
Up Q8SPP7 Peptidoglycan recognition protein 1 17 090 6.3  1012
Up P54229 Cathelicidin-5 11 722 8.0  1011
Up Q9TU03 Rho GDP-dissociation inhibitor 2 7794 1.8  107
Up P48616 Vimentin 7549 2.2  1012
Up P56425 Cathelicidin-7 7316 2.6  108
Up F1MYX5 Uncharacterized protein GN = LCP1 5417 7.3  108
Up A6QLL8 Fructose-bisphosphate aldolase GN = ALDOA 4918 8.9  1010
Up E1BLI9 Protein S100-A9 4847 7.6  1013
Up P22226 Cathelicidin-1 4743 4.3  1010
Up Q5E9F7 Cofilin-1 4636 8.6  108
Up Q9XSJ4 Alpha-enolase 4619 3.9  1011
Up Q3ZBD7 Glucose-6-phosphate isomerase 4533 5.7  108
Up Q3ZCJ8 Dipeptidyl peptidase 1 3839 3.1  106
Up P02584 Profilin-1 3799 3.7  107
Down Q8WML4 Mucin-1 102 2.3  104
Down F1MIR2 Uncharacterized protein GN = EXOC6B 119 7.5  104
Down A8YXY3 15 kDa selenoprotein GN = SEP15 123 1.4  103
Down Q9TUM6 Perilipin-2 GN = PLIN2 166 2.2  104
Down E1BN90 Uncharacterized protein GN = ZKSCAN2 221 4.3  103
Down P29392 Spermadhesin-1 327 1.3  104
Down E1BGZ9 PHD finger protein 20-like protein 1 337 2.8  103
Down F1MMF2 Uncharacterized protein (Fragment) 359 4.1  103
Down Q3ZC66 Cysteine-rich PDZ-binding protein 475 1.9  102
Down F6PZ29 Uncharacterized protein GN = MCFD2 799 2.9  104
Down Q58DJ3 KIAA1984 OS = Bos taurus 824 2.1  103
Down E1B9W6 Uncharacterized protein GN = ADCY10 2764 1.2  105
Down Q8SQ24 Myozenin-1 3030 7.2  104
Down F1MV51 Uncharacterized protein GN = APC 3282 2.5  104
Down P00711 Alpha-lactalbumin 7360 5.8  108
a False discovery rate adjusted.
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(312 h PC), both the number of differentially expressed proteins
and the fold change were smaller than at earlier infection
stages, with only 7 proteins still significantly downregulated
(Table 5), and in agreement with results from HCA and PCA,
which also showed a return to normal at 312 h PC.
3.1.4 Pathway analysis. To detect enriched canonical path-
ways and to construct functional networks in the diﬀerentially
expressed bovine proteins, IPA was used (Fig. 3 and ESI,†
Fig. S2–S5). The acute-phase response signalling pathway was
the most enriched pathway at each time point, with a positive
z-score indicating upregulation. The liver X receptor (LXR),
retinoid X receptor (LXR) and Farnesoid X receptor (FXR)
activation pathways were also enriched following intramammary
challenge. The complement system pathway showed a change
from downregulation at 36 h PC to upregulation at 81 h PC.
Interleukin (IL) 6 signalling is upregulated at 57 and 81 h PC
only. Other pathways are also up-regulated at those time points,
including Rho signalling, integrin signalling and leucocyte extra-
vasation signalling, whilst an additional pathway is up-regulated
at 81 h PC only, i.e. Cdc42 signalling (Fig. 3).
The expression of 38 proteins in the acute-phase response
signalling pathway changed over the course of the infection
(Table 6), with maximum upregulation observed from as early
as 42 h, e.g. for HRG and alpha-2-macroglobulin, to as late as
312 h for complement C1 subcomponent and retinol-binding
protein. Less than half of the proteins (n = 16) were significantly
upregulated at all time points PC. Of proteins with more than
10-fold upregulation, 5 were most strongly upregulated at 42 h,
6 at 57 h, 11 at 81 h, and 2 at 312 h. Haptoglobin was the most
strongly upregulated protein at all time points PC. SAA was also
strongly upregulated but diﬀerences were observed between
diﬀerent isoforms, whereby SAA4 showed a modest peak at
42 h PC whilst SAA1 and SAA3 showed much stronger and
later peaks in upregluation, i.e. over a 1000-fold at 81 h PC.
Interleukin-1 receptor agonist was the only protein that was
upregulated at 36 through 81 h PC and hard returned to the
pre-challenge value during the resolution phase at 312 h.
Unlike APP, the antimicrobial proteins showed strong upregula-
tion at all time points and all reached peak expression increases
of several 1000 or 10 000 fold at 57 h PC. By 312 h PC, their
upregulation levels had decreased to several 100 fold or less.
4. Discussion
In the present study, a label-free quantitative proteomics
approach was used for profiling the bovine whey proteome
during experimentally induced S. uberis mastitis. This enabled
the dynamic change in 570 proteins of the whey proteome to be
studied in synchronisation with the clinical and bacteriological
manifestations of infection,3 the peptidome4 and the meta-
bolome,9 and allowed quantification of the relative change in
multiple proteins in milk samples from the S. uberis infected
quarters. Furthermore, by examining sequential time points
following bacterial challenge, the temporal changes in important
host response pathways were revealed. Thus at 36 h post challenge,
the first time point examined, peptidoglycan recognition protein 1
and the cathelicidins, which are antimicrobial proteins (AMP)
derived from phagocytic polymorphonuclear leucocytes (PMNL)
cells that cross from the blood into the mammary gland, show the
highest fold increase, reaching a peak at 57 h PC. In contrast, APP
such as haptoglobin, LBP and SAA, derived from local synthesis in
mammary epithelia increase at a slower rate but showed their
maximal levels by 81 h PC. The concentrations in themilk samples
of haptoglobin and serum amyloid A were also measured by
immunoassay,4 giving similar increases at 57 h and 81 h and thus
serving as validation of the results obtained by the quantitative
proteomics approach. It would be of great interest to similarly
Table 5 Diﬀerentially expressed proteins at 312 hours after intramammary challenge with Streptococcus uberis
Up/down-regulated UniProt ID Protein name Fold change P-valuea
Up Q2TBU0 Haptoglobin 4191 7.4  1010
Up G3MZ19 HRPE773-like 1254 2.6  106
Up P48616 Vimentin 672 3.1  109
Up P30922 Chitinase-3-like protein 1 444 2.3  107
Up E1BKS1 Syndecan 403 8.7  106
Up P54229 Cathelicidin-5 387 7.8  107
Up F1N1Z8 Uncharacterized protein (Fragment) 348 2.6  105
Up Q8SPP7 Peptidoglycan recognition protein 1 291 5.5  107
Up F1MYX5 Uncharacterized protein GN = LCP1 246 8.7  105
Up P22226 Cathelicidin-1 226 2.4  106
Up Q8SQ28 Serum amyloid A protein 220 2.6  106
Up Q2HJF0 Similar to Serotransferrin 210 3.1  105
Up Q9XSJ4 Alpha-enolase 190 6.7  107
Up G3X746 Uncharacterized protein (Fragment) GN = CABIN1 183 4.6  103
Up P33046 Cathelicidin-4 175 3.9  104
Down E1BAU6 Uncharacterized protein GN = INPP5E 2 2.1  103
Down P02192 Myoglobin 2 6.3  104
Down P80195 Glycosylation-dependent cell adhesion molecule 1 3 3.8  103
Down Q0IIH5 Nucleobindin 2 4 3.9  105
Down E1BLC6 Uncharacterized protein GN = TTC17 67 4.3  103
Down P13696 Phosphatidylethanolamine-binding protein 1 87 2.3  104
Down Q8SQ24 Myozenin-1 642 4.9  103
a False discovery rate adjusted.
Paper Molecular BioSystems
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
4 
Ju
ly
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
4/
10
/2
01
6 
15
:0
2:
49
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
2756 | Mol. BioSyst., 2016, 12, 2748--2761 This journal is©The Royal Society of Chemistry 2016
validate by immunoassay or Western blot the results obtained for
other potential biomarkers over the course of the S. uberis IMI,
such as the cathelicidins and histidine rich glycoprotein, but this
was beyond the scope of the current investigation.
Changes in the milk proteome during mastitis due to
infection with S. uberis, S. aureus or E. coli have been studied
previously using mass spectrometry techniques.27 Many of these
studies used gel-based techniques, which are semi-quantitative,
although recently quantification using labeling such as iTRAQ or
calibration standards have been described.7,28–31 The method
used here was able to yield relative quantification of 570 proteins,
which is among the highest number that have been determined,
being exceeded only in the study of Reinhardt and coworkers7
who examined subsets of milk proteins and also depleted both
caseins and lactoglobins in order to enhance detection of low
abundance protein. In the current study only caseins were
depleted by ultracentrifugation. Method refinements introduced
here that may have enhanced protein recovery included total
protein concentration being normalized after acetone precipita-
tion and the preparation of trypsin digests using SDC as well as
acetonitrile to improve complete digestion of proteins.32,33
In a systems biology approach it is appropriate to consider
the time course of the changes in the multiple components of
milk during IMI caused by S. uberis to put the data generated
into context (Fig. 4). Many but not all of the proteome
responses to IMI found by quantitative proteomics occurred
Fig. 3 Canonical pathways enriched in the diﬀerentially expressed bovine proteins (n = 292) at 81 hours after intramammary challenge with
Streptococcus uberis. The length of the bar against each pathway shows the negative log of the p-value obtained by a Fisher’s exact test (the
significance of enrichment; the longer the better), and the colour of the bar indicates the direction and strength of regulation inferred from the activation
z-score (orange: upregulation, blue: downregulation, grey: no activity pattern available; white: z-score = 0, indicating upregulation of some proteins and
downregulation of others), with colour intensity indicating the strength of the eﬀect. The ratio is the proportion of proteins out of the entire pathway that
were identified in the dataset, e.g. for ratio = 0.10, 10% of proteins from the pathway were identified in the dataset. LXR = liver X receptor, RXR = retinoid X
receptor, FXR = Farnesoid X receptor, IL = interleukin.
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at the same time as the maximal change in peptidomic and
metabolomic responses4,9 with the maximal change in analytes
occurring at 81 h PC, at 45 h after the peak in bacterial count
(36 h PC) and, with the exception of one cow (cow 5), after rectal
temperature had returned to normal levels. This course of
events, combined with the cytokine profiles,3 supports the
interpretation that the response to bacterial challenge first leads
to cytokine release which subsequently causes the resultant
change in peptide, protein and metabolite profiles. At 36 h PC,
bacterial counts peak, clinical signs are detectable, cytokines
IL-1, IL-6, IL-8, IL-10, and IL-12p40 have been released as well as
TNF-a and there are detectable changes in the proteins and
metabolites. This coincides with massive influx of polymorpho-
nuclear leucocytes (PMNL) into the mammary gland,3 which
accounts for the increased milk somatic cell count (SCC). The
PMNL influx may be a causative event in both the reduction in
bacterial numbers and the change in peptidomic and proteomic
profiles.
The bioinformatics tools used here to examine the overall
changes taking place in the whey proteome demonstrate that
maximal responses occurred at 57 and 81 h PC, time points that
clustered by HCA. PCA demonstrated that milk samples from
Table 6 Temporal changes in acute phase proteins and antimicrobial proteins in the bovine whey proteome after intramammary challenge with
Streptococcus uberis. Acute phase proteins were identified using the ingenuity pathway analysis database with fold-change (compared to 0 h post
challenge, PC) and p-values based on one-way ANOVA (show in italics if not o0.05). Antimicrobial proteins were added for comparison. For proteins
with a fold change 410, the time point with strongest up- or down regulation is in bold. Values 410 are rounded to the nearest integer
UniProt
accession Protein name
Fold change at specified time PC (h) False discovery rate adjusted p-value at specified time PC (h)
36 42 57 81 312 36 42 57 81 312
Acute phase proteins
Q3SZR3 Alpha-1-acid glycoprotein 1.6 1.8 1.8 1.8 1.2 1  101 6  102 5  102 5  102 5  101
P28800 Alpha-2-antiplasmin 4.9 5.9 4.6 3.1 1.4 4  105 8  106 7  105 2  103 4  101
P12763 Alpha-2-HS-glycoprotein 1.4 1.8 1.7 1.2 1.4 6  102 3  103 6  103 4  101 6  102
Q7SIH1 Alpha-2-macroglobulin 68 170 128 102 33 2  104 2  105 4  105 7  105 2  103
P15497 Apolipoprotein A-I 6.3 8.0 6.8 4.1 1.5 3  105 5  106 2  105 7  104 3  101
P81644 Apolipoprotein A-II 11 22 14 5.1 1.4 4  102 1  102 3  102 2  101 8  101
Q0VCX1 Complement C1s subcomponent 1.0 1.0 2.2 20 31 1  10+0 1  10+0 4  101 4  103 1  103
Q3SYW2 Complement C2 11 8.7 19 84 81 2  102 4  102 6  103 1  104 1  104
Q2UVX4 Complement C3 1.3 1.3 1.3 1.4 2.0 1  101 1  101 1  101 6  102 4  104
F1MY85 Complement C5a anaphylatoxin 32 32 210 129 21 2  102 2  102 4  104 1  103 3  102
P81187 Complement factor B 3.2 4.1 7.4 8.2 2.8 1  104 6  106 1  108 4  109 4  104
F1N076 CP Protein 3.5 4.2 4.4 3.7 2.9 3  105 4  106 3  106 2  105 3  104
P50448 Factor XIIa inhibitor 2.5 2.4 3.0 3.2 1.2 6  103 7  103 1  103 6  104 6  101
P02676 Fibrinogen beta chain 1.2 1.9 13 9.9 7.5 8  101 2  101 2  105 1  106 5  104
F1MGU7 Fibrinogen gamma-B chain 1.7 1.1 3.4 2.9 3.1 2  101 9  101 3  103 7  103 5  103
Q2TBU0 Haptoglobin 997 4794 14 937 28 858 4191 4  108 5  1010 3  1011 6  1012 7  1010
Q3SZV7 Hemopexin 131 153 170 158 73 5  106 3  106 2  106 3  106 3  105
Q3T0D0 Heterogeneous nuclear
ribonucleoprotein K
1.0 4.7 2.5 66 1.0 1  10+0 1  101 3  101 8  105 1  10+0
F1MKS5 Histidine-rich glycoprotein 106 775 760 451 30 6  104 6  106 7  106 2  105 9  103
F1MNW4 Inter-alpha-trypsin inhibitor heavy
chain H2
51 143 78 52 38 3  103 3  104 1  103 3  103 5  103
Q3T052 Inter-alpha-trypsin inhibitor heavy
chain H4
14 21 34 38 16 5  103 1  103 3  104 2  104 3  103
Q0VC51 Interleukin 1 receptor accessory 2.4 2.4 213 267 1.0 3  101 2  101 5  108 2  108 1  10+0
O77482 Interleukin-1 receptor antagonist 30 80 325 176 1.0 2  104 8  106 7  108 5  107 1  10+0
Q2TBI0 Lipopolysaccharide-binding protein 28 84 395 693 113 2  104 5  106 2  108 4  109 2  106
C4T8B4 Pentaxin 13 7.2 45 82 1.0 6  102 2  101 8  103 3  103 1  10+0
P06868 Plasminogen 31 33 76 71 13 2  102 2  102 4  103 4  103 7  102
P00978 Protein AMBP 16 5.1 26 16 1.2 4  102 2  101 2  102 4  102 9  101
P18902 Retinol-binding protein 4 2.3 2.2 1.4 2.4 23 4  101 4  101 7  101 4  101 2  103
Q29443 Serotransferrin 4.3 5.4 5.1 4.0 2.2 2  104 3  105 5  105 4  104 3  102
A6QPQ2 Serpin A3-8 20 158 246 283 37 3  102 5  104 2  104 2  104 10  103
G8JKW7 SERPINA3 Protein 2.7 3.0 2.9 4.0 2.8 2  103 1  103 1  103 8  105 2  103
P02769 Serum albumin 1.9 2.2 2.1 1.4 1.4 6  103 1  103 2  103 2  101 1  101
F1MMW8 Serum amyloid A protein – M-SAA3.2 20 58 107 358 73 5  104 1  107 1  106 1  108 4  106
P35541 Serum amyloid A protein – SAA1 5 49 1178 1926 6.5 1  101 2  103 6  107 2  107 1  101
Q8SQ28 Serum amyloid A protein – SAA3 93 201 556 1585 220 4  105 3  106 2  107 8  109 3  106
Q32L76 Serum amyloid A protein – SAA4 17 66 27 10 2.0 4  102 3  103 2  102 9  102 6  101
O46375 Transthyretin 2.4 2.2 1.9 1.3 1.2 3  103 7  103 3  102 3  101 5  101
Antimicrobial proteins
P22226 Cathelicidin-1 1026 3812 7281 4743 226 3  108 8  1010 1  1010 4  1010 2  106
P19660 Cathelicidin-2 78 1159 2104 1683 38 6  103 4  105 1  105 2  105 2  102
P33046 Cathelicidin-4 208 2619 4753 2963 175 3  104 1  106 3  107 8  107 4  104
P54229 Cathelicidin-5 1444 9209 16 618 11 722 387 2  108 2  1010 3  1011 8  1011 8  107
P56425 Cathelicidin-7 1217 8922 11 877 7316 178 2  106 2  108 9  109 3  108 3  102
Q8SPP7 Peptidoglycan recognition protein 1 3305 8453 27 479 17 090 291 5  1010 4  1011 2  1012 6  1012 6  107
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81 h PC were the most divergent from the pre-challenge
samples while samples from 312 h PC, i.e. the resolution
phase, were being restored towards, but were still distinct
from the pre-challenge clusters, even though 5 cows had
cleared the infection at that point.3 Pathway analysis using
IPA identified the APP pathway as having the largest change
of any pathway at all time points, supporting the evidence
from investigations using immunoassay and transcript analysis
that these proteins are among those most aﬀected by IMI.4,34
The second and third most aﬀected pathways were the LXR/RXR
activation and FXR/RXR activation pathways, incorporating liver
(LXR), retinoid (RXR) and farnesoid (FXR) receptor related
proteins. However, a number of APP are also components of
these pathways and lead to identified up-regulation by IPA due
to this cross-recognition. The IPA also showed that although
the PMNL influx increases rapidly between 24 and 42 h post-
challenge,3 the leucocyte extravasation signalling pathway was
only enriched at 57 and 81 h PC, indicating that there may be a
lag between initial influx and detectable levels of protein
upregulation in this pathway. Similarly, IL-6 levels were signifi-
cantly elevated at 36 and 42 h PC based on ELISA assays,3 but
enrichment of the IL-6 pathway was not detected until 57 h PC
by proteomic analysis and IPA.
Like IPA, analysis of diﬀerential protein expression profiles
identified APP as being central to the pathophysiological
changes following S. uberis challenge. In addition, several
AMP featured in the lists of proteins with the highest fold increase
in expression. The AMP are a diverse group of proteins that show
antimicrobial activity. They are secreted by PMNL and function as
primary eﬀectors of innate immunity in the mammary gland.35
Among the AMP, cathelicidins and peptidoglycan recognition
protein 1 were strongly upregulated from 36 h PC onwards, with
expression levels 1000s of times higher than before challenge.
Indeed, cathelecidin-5 and peptidoglycan recognition protein
showed the largest fold increase of any of the proteins quantified
by LC-MS/MS up to and including 57 h PC. Previous studies also
reported up-regulation of AMPs, particularly cathelicidins, in
mastitic milk.6,7 Other AMPs, e.g. lactoperoxidase and mucin,
which is thought to be an inducible innate immune eﬀector,36
were detected at lower level after challenge, which could indicate
decreased expression, or increased use without replenishment.
Interestingly, the highest levels of cathelicidins were detected
from 42 to 81 h, a period that coincides with a massive decrease
in bacterial numbers3 from an average of 108 cfu ml1 down to
104 cfu ml1, and cathelicidin expression decreased after this
reduction in cfu count. Unlike some other mastitis pathogens,
Fig. 4 The relative responses of analytes following experimental induced S. uberis mastitis combining proteomic results with data from Tassi et al.3 and
Thomas et al.4 The shading represents strength of the response relative to the peak response Responses were increases compared to day 0 levels except
for casein levels (indicated by *), which decreased after challenge. cfu = colony forming unit; SCC = somatic cell count; TNF = tumor necrosis factor;
1DGE = 1 dimensional gel electrophoresis; (m)SAA3 = (milk) derived serum amyloid A; IMI77 = peptidomic profile based on 77 peptides.
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S. uberis is resistant to phagocytosis and killing by neutrophils.37
The massive increase in cathelicidin levels, which followed PMNL
influx and preceded or coincided with bacterial clearance, may
provide an alternative mechanism by which PMNL contribute to
resolution of IMI caused by S. uberis.
As the acute-phase response is a swift systemic inflammatory
reaction in response to infections and is already implicated in
responses to IMI38,39 it is no surprise that changes were found
among the APP in this investigation. However, the profile of
changes in multiple APP, in response to the S. uberis challenge,
was shown here in much more detail than has been previously
possible and within the APP, diﬀering profiles were found.
A number of the APP showed their highest fold increase at 42 h
PC. Thus, alpha-2-macroglobulin and HRG had fold changes of
170 and 775 respectively at this time point. In contrast, a
number of APP showed continuing elevation in their fold
increase up to 81 h PC with haptoglobin, SAA1 and LBP having
fold increases of 28 858, 1926 and 693 respectively. The
diﬀerences found in the profile of responses of the APP are
likely to be due to cellular mechanisms in the control of
their synthesis and release, dependent on the cytokine cocktail
developed in response to infection.40,41 Cytokine profiles diﬀer
between bacterial species42 and hence diﬀering profiles of both
the APP and AMP responses can be expected for diﬀerent
mastitis pathogens. Further investigation of these profiles and
of interaction with the peptide and metabolomics changes4,9
may lead to multiplexed biomarker analysis capable of providing
pathogen specific diagnosis which would be of great value in
mastitis diagnosis and therapy.
Examining the expression of individual APP, increased
expression of haptoglobin is known to occur during mastitis38,43
and has been quantified previously in proteomic investigation.44,45
It was apparent that Hp detection by quantitative proteomic
analysis was more sensitive than detection by ELISA, as sub-
stantial increases in Hp levels were detected at 36 h PC in by the
proteomic approach, but not by Thomas and colleagues where
ELISA was used.4 The high fold increase of Hp which was still
present at 312 h PC at 4191 indicates that Hp may be useful as
an indicator of high SCC, which was still high at that time, but
may have limited value as indicator of the IMI, which had been
resolved in 5 of 6 animals.3 SAA, in the isoforms found here, also
reached a maximum at 81 h PC. These are a family of apolipo-
proteins that are associated with high density lipoprotein when
in serum.38 The mammary associated SAA3 isoform is also one
of the first APP reported to increase during mastitis and previous
proteomics studies have shown up-regulation of isoforms of
SAA in milk in response to gram-negative and gram-positive
pathogens.6,7,38 As for Hp, proteomic analysis identified the
increase in SAA levels earlier than ELISA-based analysis4 demon-
strating further that quantitative proteomics may be more
sensitive than the forms of ELISA used previously. However the
use of relative quantitation may give a misleading impression of
the change taking place when the level of the protein in the
control (0 h PC) is very low or not detectable in the LC-MS/MS
analysis. Absolute quantification by calibrated standard in quan-
titative proteomics or in immunoassay is needed to determine
the change in the absolute concentration of the milk proteins
in IMI.
Among the APP with an early maximum fold increase at 42 h
PC, alpha-2-macroglobulin is a protease inhibitor that can
inhibit all four classes of proteases (serine, cysteine, aspartyl
and metalloproteases). It is present in milk in its native,
active state and its concentration is known to increase during
mastitis.7,46 HRG was also identified as an early elevated APP
and is a major plasma protein in a range of mammals, including
cattle.47,48 It plays a role in blood coagulation, fibrinolysis, and
innate immune systems and is also thought to have antibacterial
properties.48 As HRG was upregulated as early as 36 h PC and
was returned to normal levels towards the end of the experiment,
it may have a role as a diagnostic marker in detecting the
occurrence and resolution of IMI. However, the only protein
with significantly increased expression at 36 h PC which had
returned to pre-challenge levels in the resolution phase was
interleukin-1 receptor agonist. During the resolution phase of
IMI (57 to 312 h PC), increased levels of vimentin were detected.
Vimentin is a fibroblast marker, whilst there are conflicting
reports on its presence in myoepithelial cells.49,50 Its elevated
expression in milk would appear to indicate damage or repair of
the subalveolar tissue of the mammary gland.
In addition to quantifying host proteins in whey, we
attempted to quantify bacterial peptides and identify bacterial
proteins using the S. uberis reference proteome (data not shown).
Despite massive increase in bacterial numbers over the course of
infection with peak concentrations around 108 colony forming
units per ml of milk,3 diﬀerential expression analysis showed
much lower fold increases than for bovine proteins (maximum
of 706 fold increase for a bacterial putative lipoprotein versus
maximum of 28858 fold change for haptoglobin). Separation
of bacteria from whey or other modifications to the sample
processingmethods may be needed for better characterisation of
the bacterial proteome during IMI.
5. Conclusion and outlook
Using a label-free relative quantification method, changes in
protein expression in bovine whey in an experimental model of
S. uberis mastitis have been determined. In particular, the
dynamic changes in the proteome during establishment and
resolution of infection, with emphasis on APP and AMP has
been determined. Our results were in agreement with previous
proteomic studies but provide a time-course rather than a
snapshot of protein profiles. Proteins that have not been
previously associated with mastitis, including HRG, an acute-
phase and antimicrobial protein, have been quantified. In addition,
the time course of events observed in our linked studies provides a
potential explanation for the clearance of S. uberis after influx of
PMNL, whereby cathelicidins produced by the PMNL rather than
neutrophil phagocytosis and killing may be the main eﬀector
mechanism. Quantitative proteomics has provided an additional
layer of analysis to the milk whey samples obtained during the
experimental model of bovine mastitis caused by S. uberis and by
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integration with the pathophysiological, molecular, peptidomic
and metabolomics analyses performed on the same sample set
has enabled a more comprehensive, systems level view of the host
responses to bovine mastitis than has been achieved previously.
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